News>
BioPorto adjusted EBITDA loss narrows 11% to DKK 16.3 million in Q2 2026; revenue drops 35% to DKK 6.9 million vs Q2 2025
- BioPorto posted Q2 revenue of DKK 6.9 million, down 35% year over year, hit by the antibody business divestment and a voluntary recall.
- NGAL revenue slipped 15% to DKK 6.4 million in Q2; adjusted for the recall impact, NGAL revenue totaled DKK 9.2 million.
- Adjusted EBITDA loss narrowed 11% to DKK 16.3 million; cash stood at DKK 75.6 million at June 30.
- Activated a US ProNephro AKI Adult Urine NGAL validation study expanded to about 900 patients; FDA clearance now expected mid-2028.
- Confirmed 2026 outlook: revenue DKK 38-48 million, NGAL revenue DKK 33-42 million, adjusted EBITDA loss DKK 58-68 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioPorto A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200155OMX_____CNEWS_DA_GNW1001258456_da) on August 20, 2026, and is solely responsible for the information contained therein.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Trade now！
You may also like
Crypto prices
More
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now